UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
August 2, 2006 (July 27, 2006)
_______________
DIALYSIS CORPORATION OF AMERICA
(Exact name of registrant as specified in its charter)
Florida 0-8527 59-1757642
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
1302 Concourse Drive, Suite 204, Linthicum, MD 21090
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (410) 694-0500
_______________
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of
the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 1.01 Entry into a Material Definitive Agreement
On October 24, 2005, Dialysis Corporation of America (the "Company")
entered into a Credit Agreement with Keybank National Association
("Keybank"), pursuant to which Keybank has provided the Company with a $15
million secured revolving credit facility (the "Credit Agreement") by means
of any combination of base rate loans and/or LIBOR loans. The Credit
Agreement was reported in a Current Report on Form 8-K dated October 27,
2005. Keybank and the Company entered into Amendment No. 3 to Credit
Agreement excluding from Indebtedness insurance premium financing, and
allowing liens the insurance company may obtain to secure such financing,
provided any such liens are only for unearned premiums under relevant
policies and return premium endorsement payments.
The proceeds of the Credit Agreement are used for development and
acquisition of new dialysis centers, working capital needs, and for other
general corporate purposes.
Item 2.03 Creation of a Direct Financial Obligation or an Obligation Under an
Off-Balance Sheet Arrangement of a Registrant
The information relating to the Company's entry into Amendment No. 3 to
Credit Agreement is set forth in Item 1.01 above, and is incorporated in this
Item 2.03 by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
(10) Material Contracts
(i) Amendment No. 3 to Credit Agreement between the Company and
Keybank National Association dated July 27, 2006
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
DIALYSIS CORPORATION OF AMERICA
/s/ Stephen W. Everett
By------------------------------------
STEPHEN W. EVERETT
President and Chief Executive
Officer
Dated: August 2, 2006
EXHIBIT INDEX
Exhibit
Number
-------
(10) Material Contracts
(i) Amendment No. 3 to Credit Agreement between the Company and
Keybank National Association dated July 27, 2006